A Case of Erdheim-Chester Disease Developed during Treatment of Leukemia in a Child

Joon Pyo Hong, M.D., Won Ki Ahn, M.D., Joo Yeon Lim, M.D., Jo Eun Jung, M.D., Seung Min Hahn, M.D., Ph.D., Jung Woo Han, M.D., Ph.D. and Chuhl Joo Lyu, M.D., Ph.D.

Division of Pediatric Hematology and Oncology, Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea

Erdheim-Chester disease (ECD) is a rare non-Langerhan’s cell histiocytosis disorder characterized by replacement of normal tissue by lipid-laden histiocytes affecting various organs. A few pediatric cases have been reported worldwide. Here we present a child with leukemia who was diagnosed as ECD. A 2-year and 11-month old boy diagnosed with high risk acute lymphoblastic leukemia (ALL) at the age of 17 months, received allogeneic hematopoietic stem cell transplantation (HSCT) at the age of 2 years old. Six months after the transplantation, the patient was admitted to the hospital with palpable left calf nodules. Bone marrow study suggested ECD without leukemia with complete chimerism status. Excisional biopsy of the left calf nodule showed ‘aggregation of non-Langerhan’s cell type epitheloid histiocytes’; clinically suggestive of ECD. The patient was started on vinblastine and corticosteroid treatment.

Key Words: Erdheim-Chester disease, Acute lymphoblastic leukemia, Child

Erdheim-Chester disease (ECD) is an infiltrative form of histiocytosis characterized by replacement of normal tissue by lipid-laden histiocytes. ECD was first described in 1930 by Jacob Erdheim and William Chester [1]. ECD is categorized as a non-Langerhans cell histiocytosis affecting various organs with a wide range of manifestations and its incidence is extremely rare; as of January 2013, approximately 500 cases had been reported worldwide, but these numbers have recently shown a rapid increase, with more than 300 new cases published in the last 10 years [2]. ECD involves xanthomatosus or xanthogranulomatous infiltration of tissues by foamy histiocytes, “lipid laden” macrophages, or histiocytes, surrounded by fibrosis. ECD is, therefore, mostly diagnosed by histological analysis; polymorphic granuloma infiltrated with CD68-positive and CD1a-negative...
foamy histiocytes [2,3]. Recent findings suggest that ECD is a clonal disorder, marked by recurrent BRAF V600E mutations (>50% of patients diagnosed with ECD) activating MAPK signaling, in which there is not only inflammation driven by aberrant immune activation, but also myeloid neoplasia as a potentially important pathogenesis of disease [4]. The usual onset of ECD is middle age, and it is rarely seen in pediatric patients [2]. Here we present a case of 2-year-old patient diagnosed with ECD who underwent allogeneic hematopoietic stem cell transplantation (HSCT) due to acute lymphoblastic leukemia (ALL).

**Case Report**

A 2-year and 1-month-old Korean boy was born without any complications and grew up without any health problems. On November 2014, he was admitted to our department with a pale face and leukocytosis of 171,500/µL on complete blood cell count (CBC). The 1st bone marrow study showed early pre-B cell ALL with no abnormal gene translocations on PCR, and 46, XY normal male karyotype with hyperdiploidy on chromosome test. Since he had severe leukocytosis on initial CBC, we started high-risk ALL induction chemotherapy and planned for allogeneic HSCT. After induction and consolidation chemotherapy, the follow-up bone marrow study showed complete remission. However, after interim-maintenance chemotherapy, a bone marrow study showed blast cells constituting 2.8% of absolute neutrophil count and aggregation of epithelioid histocytes and foamy macrophages, which highly suggested ECD or disseminated juvenile xanthogranuloma. However, the patient did not show any systemic lesions or symptoms correlated with ECD and we decided to continue with regular observation. The patient then underwent allogeneic HSCT and a bone marrow study 1 month after the transplantation and still showed solid aggregates of large atypical histiocytoid cells with mixed chimerism state. On January 2016, 7 months after the transplantation, the patient was admitted to the emergency department with fever, lower eyelid swelling and palpable left calf nodules.

Laboratory test results including CBC, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), electrolyte and culture studies were relatively normal with mild elevations of ESR and CRP. Paranasal sinus (PNS) Computed tomography (CT) scan showed orbital cellulitis with possible involvement of Lt. nasolacrimal duct and a 1.8 cm exophytic mass lesion (Fig. 1). A whole body bone scan was done to evaluate leg pains and it showed diffusely increased uptake in the entire skeleton. The bone marrow study was performed to exclude leukemic or malignant involvement, and aggregation of epithelioid histiocytes was seen, which is highly suggestive of ECD with complete a chimerism state of the bone marrow (Fig. 2A). The patient subsequently underwent excisional biopsy of the left calf mass lesion. The pathology results were ‘aggregation of non-Langerhans cell type epithelioid histiocytes with acute

![Fig. 1. PNS CT scan. (A) The red square outlines the 1.8 cm mass-like soft tissue infiltration on the inferior orbital wall. Ultrasonography. (B) Marked area shows the small 0.7 cm cystic mass lesion in the subcutaneous layer of left medial popliteal space.](image-url)
Fig. 2. Bone marrow biopsy. (A) Aggregation of epithelioid histiocytes is seen in the bone marrow study. The encircled cytosol-rich cells are foamy macrophages shown in the bone marrow (×200). Left calf nodule biopsy. (B) Aggregation of non-Langerhans cell type epithelioid histiocytes with acute inflammation are seen. The long and relatively thin cells seen in the red circle are histiocytes (×200). (C) Histiocytes circled, long and thin band-like cells are observed at in most of the site (×400).

Fig. 3. Immunostaining of left calf nodule biopsy shows CD68 and CD163 positive cells.

inflammation with CD163+, CD68+ and BRAF mutations (+)’ clinically suggestive of ECD (Fig. 2B, C and Fig. 3).

The patient started weekly vinblastine chemotherapy and corticosteroids after pathologic confirmation of ECD. Within 2 weeks of treatment with vinblastine, the patient’s symptoms of fever and bone pain started to disappear. After 2 months of treatment with vinblastine, a follow-up bone marrow study and whole body bone scan were performed. The bone marrow study revealed no pathologic evidence of ECD with complete chimerism state and the bone scan showed decreased intensity of diffuse uptake throughout the whole skeleton. The patient is still undergoing vinblasticine treatment.

Discussion

ECD is a rare, non-Langerhans cell histiocytic disease with various clinical manifestations. ECD typically affects the long bones and often shows symmetrical sclerosis in the diaphyseal areas. Extra-skeletal involvement such as lung, cardiovascular, liver, spleen, retroperitoneum and central nervous system, can be seen in ECD and the extent of disease affects its prognosis [2]. Treatment of ECD has not been standardized yet. The types of treatment include corticosteroids, cyclosporine, chemotherapy (e.g., vinblastine, cyclophosphamide, etoposide, 6-mercaptopurine, and doxorubicin), interferon-alpha, surgical resection and radiotherapy, all of which have variable responses [5]. Among these treatment choices, interferon-alpha seems to be the best choice for the initial prolonged treatment of ECD considering the survival rate [5]. However, recent studies have shown that 57 to 82% of patients with ECD harbor a BRAF V600E mutation [4]. Of these studies, two researches, one from the French Histiocytosis Study Group and one from Memorial Sloan Kettering Cancer Center (MSKCC), have shown that targeted therapies (vemurafenib; BRAF inhibitor) in adult patients with BRAF-mutated histiocytosis have a dramatic and highly consistent efficacy [6,7]. Along with these two studies, there are some other reports worldwide that suggest targeted therapies with BRAF inhibitors (e.g.,
vemurafenib, dabrafenib) are effective for treatment of ECD patients with BRAF mutations [8]. Moreover, MSKCC has recently shown that MEK inhibitors (trametinib, cobimetinib) are rapidly effective in patients with histiocytic neoplasm, which led to the development of clinical trials targeting BRAF wild-type adult histiocytosis [9]. In our case, we are treating the patient with weekly vinblastine and corticosteroids. Interferon alpha had been our first treatment consideration, but steroids and vinblastine was tried first due to the patient’s refusal of a long hospital stay. Though in continuation, treatment seems to be quite effective so far. According to numerous recent reports and studies of targeting BRAF, MEK, and mTOR in histiocytosis treatment, mutation targeted therapy might be an efficient and standard treatment for ECD in the future. However, a large, multi-center approach of using BRAF inhibitors or MEK inhibitors in pediatric patients has not been studied yet. In terms of safety along with efficacy, more clinical trials and studies of treating ECD child patients with BRAF/MEK inhibitors are needed to establish a standard treatment guideline for children with ECD.

Our case also shows the concurrence of ECD with ALL, which is extremely rare. The first time histiocytes were noted in bone marrow biopsy was right after treated with interim-maintenance chemotherapy before allogeneic HSCT. We just decided to have careful observation without any further treatment since no other symptoms were present. However, after allogeneic HSCT, symptoms mentioned in the case report have appeared and found that ECD was the cause. Since ECD is a very rare disease, we carefully think that ECD seen in the bone marrow after allogeneic HSCT is of recipient origin rather than donor origin. Only two cases of ECD in a child with acute lymphoblastic leukemia (ALL) have been reported so far; a 14-year-old girl who was in remission with pre-B acute lymphocytic leukemia, subsequently diagnosed with ECD [10] and a 6-year-old girl diagnosed with ECD during maintenance therapy for B-cell ALL [11]. Although extremely rare, considering Langerhans cell histiocytosis (LCH), which has been reported to have a close relationship with several malignancies [12], ECD might also have coincidences with some malignancies. Though it is rare, it is reported that acute leukemia is the most common malignancy associated with LCH [12]. Several reports suggest that coincident LCH and ALL is due to the fact that they share the same mutation or have an identical T-cell receptor or immunoglobulin rearrangement [13]. Moreover, there is a recent report of high prevalence of myeloid neoplasm in adults with non-Langerhans cell histiocytosis [14]. They say that driver mutations in myeloid neoplasm (such as JAK2V617F and CALR mutations) have been frequently detected with coexisting mutations (such as BRAFV600E and MAP2K1 mutations) which are known to be characteristics of histiocytosis. Unfortunately, we did not examine the cytogenetic studies of this patient with ECD aside from the BRAF mutation. Therefore, we could not identify the pathogenesis of this concurrence of ECD and ALL. It is difficult to say whether there is a considerable chance of occurrence of ECD during or after ALL treatment at this time. However, because more than half of the ECD patients harbor BRAF mutations and reports of recurrent RAS and PIK3CA mutations found in ECD patients [15], ECD might occur with some malignancies including acute leukemia, owing to the fact that they share same mutations or genetic rearrangement finding in cytogenetic studies.

References


